BriefMD

Specialties / Allergy & Immunology

New Allergy & Immunology research.

The strongest recent Allergy & Immunology papers on PubMed, ranked by study design, topic and journal, with the same summaries subscribers get.

  1. randomized trial

    Long-term efficacy of lebrikizumab in treating head, neck and face involvement in patients with moderate-to-severe atopic dermatitis

    Chovatiya R, de Bruin-Weller M, Alexis A, et al. J Dermatolog Treat. Dec 2026.

    Findings
    In week‑16 responders, 94.8% maintained HN EASI‑75, 82.9% HN EASI‑90, and 85.3% HN EASI‑100 at week 152 (3 years).
    Bottom line
    Lebrikizumab provides durable HN‑area control with >94% retaining EASI‑75 at 3 years.

    PubMed, PMID 42895209

  2. meta-analysis, 35 studies

    Paediatric Helicobacter pylori infection and allergic and inflammatory diseases: a contemporary systematic review with meta-analysis

    Tavares M, Ferreira A, Campo E, et al. Eur J Pediatr. Oct 2026.

    Findings
    The meta‑analysis found an overall odds ratio of 0.75 for asthma, with a 95% confidence interval of 0.54‑1.05 and heterogeneity I² = 67.3%. Subgroup analysis showed an inverse association in studies using UBT/SAT, while histology‑based studies showed no association.
    Bottom line
    Overall OR = 0.75 (95% CI 0.54‑1.05); I² = 67.3% indicates substantial heterogeneity.

    PubMed, PMID 42895565

  3. phase ii trial, 200 patients

    Efficacy and safety of QY201, an oral dual Janus kinase 1/tyrosine kinase 2 inhibitor, in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2 dose-finding trial

    Wang T, Li J, Liang Y, et al. J Am Acad Dermatol. Oct 2026.

    Findings
    In a 200‑patient phase‑2 RCT, QY201 10 mg BID produced an 84.7% EASI‑75 response at week 12 versus 18.5% with placebo (P<0.0001). Higher doses also improved IGA scores (up to 71.3% vs 12.4% placebo) and showed TEAEs in 75–90% of participants.
    Bottom line
    QY201 10 mg BID markedly increases EASI‑75 response (84.7% vs 18.5% placebo) with a safety profile comparable to lower doses.

    PubMed, PMID 42901423

  4. systematic review, 24 studies

    Local Delivery of Interferon-β1a for Respiratory Viral Infections: A Systematic Review

    Nayebhashemi M, Akhavan M, Foroohari A, et al. Rev Med Virol. Nov 2026.

    Findings
    The review identified Twenty-four studies meeting the inclusion criteria, including 12 RCTs, seven in vitro studies, one in vivo study, and four patent reports. Clinical studies demonstrated consistent antiviral activity and immune modulation (e.g., ISG upregulation, viral load reduction).
    Bottom line
    Twenty-four studies met the inclusion criteria, and clinical studies showed consistent antiviral activity and immune modulation.

    PubMed, PMID 42925549

  5. systematic review, 81 studies

    Biologics and JAK inhibitors for atopic manifestations in inborn errors of immunity: a systematic review

    Jamee M, Al-Gaweesh RM, Hajialigol A, et al. Front Allergy. Jan 2026.

    Findings
    The systematic review identified STAT3 loss-of-function disease (n = 52, 30.2%), Netherton syndrome (n = 32, 18.6%), and DOCK8 deficiency (n = 19, 11.0%) as the most common inborn errors of immunity treated with biologics or JAK inhibitors.
    Bottom line
    STAT3 LOF, Netherton syndrome, and DOCK8 deficiency together account for the majority of cases, representing 30.2%, 18.6% and 11.0% of the cohort respectively.

    PubMed, PMID 42908597

Summaries are written by AI from PubMed abstracts, for keeping up with the literature. Check the source before it changes care. Editorial policy · Medical disclaimer

Get Allergy & Immunology research every morning.

Free. Choose your Allergy & Immunology topics after you subscribe.